Ultragenyx Pharmaceutical has entered into pharma deals with Kyowa Hakko Kirin, to develop and commercialize KRN23.
KRN23, the compound being licensed in the pharma deals, is a recombinant fully human monoclonal IgG1 antibody intended to treat X-linked hypophosphatemia.
KHK is currently completing a Phase 1/2 study in adults with XLH in the US and Canada, prior to these pharma deals.
The two companies plan to initiate a pediatric XLH program in 2014, as part of other pharma deals.
Report: Partnering Deals and Alliances with Kyowa Hakko Kirin
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity